MIST - Pangali EV/EBITDA Milestone Pharma

Milestone Pharmaceuticals (MIST) ensures reliable cold-chain delivery of cardiac medications, mitigating customs risks to maintain high profitability. This price chart, featuring an EV/EBITDA metric of 0.00, illustrates the company during a period of intensive clinical trials for a high-demand heart rhythm control agent. The business's financial success is based on the market launch of innovative nasal sprays designed to curb tachycardia attacks.

MIST Milestone Pharmaceuticals Inc: Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 10.11.2026

MIST (milestonepharma.com): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:

Bagan rega Milestone Pharma|MIST - Bagan rega target

- statistik kapitalisasi pasar:

Kapitalisasi pasar Milestone Pharmaceuticals Inc|MIST - Total Nilai Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Milestone Pharmaceuticals|MIST - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih milestonepharma.com|MIST - Aset Agregat Bisnis

- data utang lan likuiditas:

Utang marang Ekuitas Milestone Pharmaceuticals|MIST - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Milestone Pharmaceuticals Inc.|MIST - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Milestone Pharmaceuticals Inc|MIST - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Milestone Pharmaceuticals|Likuiditas cepet milestonepharma.com

- data bathi bisnis lan rasio investasi:

MIST - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Milestone Pharmaceuticals|MIST - Nilai perusahaan marang bathi resik|Pangali Forward P/E Milestone Pharmaceuticals|MIST - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Milestone Pharmaceuticals Inc|MIST - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Milestone Pharmaceuticals|MIST - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan milestonepharma.com|MIST - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Milestone Pharmaceuticals

Pambiji fundamental perusahaan:Milestone Pharma MIST

Produk asli Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals (MIST) is developing an emergency cardiac care system by introducing nasal sprays to treat tachycardia outside of clinical settings. An analysis of the company's current EV/EBITDA ratio allows for a comparison of the total enterprise value, including net debt, against its operating profit. This metric eliminates the impact of tax regimes and depreciation, revealing the actual efficiency of cash flow generation. A decline in this indicator confirms that assets are undervalued, creating an entry point for the long-term investor.

Analisis pesaing